A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection
Xiujuan Chang,Jing Wang,Yan Chen,Qinghua Long,Laicheng Song,Qin Li,Huabao Liu,Qinghua Shang,Zujiang Yu,Li Jiang,Guangming Xiao,Li Li,Liang Chen,Xiaodong Wang,Zhiqin Li,Da Chen,Zheng Dong,Linjing An,Lin Tan,Yongping Chen,Yongping Yang
DOI: https://doi.org/10.1016/j.ebiom.2021.103389
IF: 11.205
2021-05-01
EBioMedicine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>HBeAg-positive chronic infection is a unique phase of chronic hepatitis B virus (HBV) infection. Current guidelines advise against starting antiviral treatment for HBeAg-positive chronic hepatitis B virus (HBV) infection patients, some data suggest treating such patients may reduce the risk of hepatocellular carcinoma. We aimed to explore whether these patients can have evident histological liver injury (EHLI), and develop a non-invasive model for identifying EHLI in such patients.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Method</h3><p>We assessed whether HBeAg-positive chronic HBV infection patients can have EHLI defined by Ishak fibrosis stage ≥3 and/or histologic activity index ≥ 9 in a prospective multicenter study. Logistic and Lasso regression was used to select the optimal predictors. We used Akaike information criterion, discrimination improvement, net reclassification improvement to develop and validate models predicting EHLI risk in training cohort and two external validation cohorts.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>Of these 336 patients met the inclusion criteria, 181(54%) were HBeAg-positive chronic HBV infection, of whom 60 patients (33%) had EHLI, the proportion of significant fibrosis was higher than that of significant inflammation (33% vs. 8%, <em>P</em> < 0.001). Age, liver stiffness measurement, ALT, alkaline phosphatase, and albumin were identified as independent predictors for EHLI and used to develop a nomogram that have been demonstrated having a good performance in predicting EHLI with AUROCs of 0.92(95%CI: 0.86–0.99) in the training cohort (<em>n</em> = 233) and 0.90(95%CI: 0.84–0.95) in validation cohort 1(<em>n</em> = 103), significant correcting current guidelines recommendations overestimating insignificant or significant histological disease. After 72-weeks entecavir treatment for HBeAg-positive chronic HBV infection patients with EHLI identified by nomogram, histological improvement occurred in 40 of 49(82%), 38(78%) had fibrosis reversal, and 35(73%) no longer had EHLI.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interpretation</h3><p>In HBeAg-positive chronic HBV infection patients, 33% has EHLI. The nomogram developed in this study can accurately identify HBeAg-positive chronic HBV infection patients with EHLI, and that responded very well to antiviral therapy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Funding</h3><p>This study was funded by the State Key Projects Specialized on Infectious Disease, Chinese Ministry of science and technology (2013ZX10005002; 2018ZX10725506), National Natural Science Foundation of China (81970525) and Beijing Key Research Project of Special Clinical Application (Z151100004015221).</p>
medicine, research & experimental